There is plenty of discussion that can be had when referring to the condition known as glioblastoma. Viewed as the very condition that took the life of Senator Edward Kennedy a few years ago, it is seen as the most aggressive and common condition in the brain. As a result, therapies are built and drugs are tested in order to see which of these can yield the greatest of the results. After reading about the inclusion of HSPPC-96, I think that there is even more discussion that can be made by Stuart Millheiser and others.
News-Medical posted an article that spoke about an experimental vaccine that could be used in order to help those who have this condition. It would entail a degree of tumor tissue, which is needed in order to make it impactful. As the article would go on to state, patients saw increased levels of survival in comparison to what they might have had with only standard methods of care. There is quite a bit to talk about when it comes to the phase 2 trial tied to this vaccine.
When it comes to the most serious conditions in the human body, whether it's ALS or what have you, glioblastoma stands amongst them. The article went into detail about these tumors and how they seem to accelerate rather quickly, which does little to help the treatment methods that exist. Amongst them, common invasive surgery alongside chemo and radiation is viewed as the most typical procedure to help those with this condition. These stories are rightfully covered by various names, Stuart Millheiser being just one of the names to consider.
The way that the phase 2 trial worked was that 41 adult patients were given a vaccine in an average of six doses. The vaccine in question is known as HSPPC-96 and it was administered in those with tumors from 2007 to 2011. According to the report, 90 percent of the patients were alive at six months and 30 percent of them were alive at one year. It probably goes without saying that further work has to be done in order to see if this will be a solid treatment for cancer in general. Judging by the results, the potential is present and Stu Millheiser can agree.
Treatment is one of those ideas linked to glioblastoma research that is constantly being worked on. It seems as though treatment in general is one of the broadest areas to consider as well and the fact that there are so many details to consider speaks volumes. Stem cells have been put to use in the past, so the tissue from tumors should be utilized if there are incentives to consider. To me, this goes to show that the degree of potential will prove to be one of the greatest.
News-Medical posted an article that spoke about an experimental vaccine that could be used in order to help those who have this condition. It would entail a degree of tumor tissue, which is needed in order to make it impactful. As the article would go on to state, patients saw increased levels of survival in comparison to what they might have had with only standard methods of care. There is quite a bit to talk about when it comes to the phase 2 trial tied to this vaccine.
When it comes to the most serious conditions in the human body, whether it's ALS or what have you, glioblastoma stands amongst them. The article went into detail about these tumors and how they seem to accelerate rather quickly, which does little to help the treatment methods that exist. Amongst them, common invasive surgery alongside chemo and radiation is viewed as the most typical procedure to help those with this condition. These stories are rightfully covered by various names, Stuart Millheiser being just one of the names to consider.
The way that the phase 2 trial worked was that 41 adult patients were given a vaccine in an average of six doses. The vaccine in question is known as HSPPC-96 and it was administered in those with tumors from 2007 to 2011. According to the report, 90 percent of the patients were alive at six months and 30 percent of them were alive at one year. It probably goes without saying that further work has to be done in order to see if this will be a solid treatment for cancer in general. Judging by the results, the potential is present and Stu Millheiser can agree.
Treatment is one of those ideas linked to glioblastoma research that is constantly being worked on. It seems as though treatment in general is one of the broadest areas to consider as well and the fact that there are so many details to consider speaks volumes. Stem cells have been put to use in the past, so the tissue from tumors should be utilized if there are incentives to consider. To me, this goes to show that the degree of potential will prove to be one of the greatest.
About the Author:
For additional information in regards to ALS and Stu Millheiser, overall, contact Stuart Millheiser today.
No comments:
Post a Comment